BioSpace News Archive

Reference is made to the stock exchange notice by Nordic Nanovector ASA, of 7 May 2020, regarding the share capital increase in relation to certain board members’ exercise of RSUs.

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, announced that the company has entered into a collaborative research agreement with Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science.

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that its drug Silmitasertib was again identified as one of the top potential treatments against COVID-19.

Findings demonstrate pre-procedural use of the company’s revolutionary 3D printed, patient-specific simulation models provides significant training and rehearsal advantages [01-July-2020] BOSTON , July 1, 2020 /PRNewswire/ -- BIOMODEX®, a pioneering digital health company that offers a unique and enhanced 3D printed solution for patient-specific rehearsal and physic

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today the appointment of veteran biotech executive and Chairman of FibroGen, Inc., Jim Schoeneck, to its Board of Directors. Throughout his career in the biotech and pharmaceutical industry, Schoeneck has served as CEO of five biotechnology and specialty pharmaceutical companies, inc

Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, today announced the appointment of Torsten Hombeck, Ph.D., as Chief Financial Officer and member of the Company’s executive team. Dr. Hombeck has over two dec

Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announces that it has entered into a Securities Purchase Agreement (the “Agreement”) of up to $30 million with Aspire Capital Fund, LLC (“Aspire Capital”)

BioNTech SE (Nasdaq: BNTX, “BioNTech”) will host a conference call and webcast today, July 1 st , 2020 at 11:00 a.m. EDT (5:00 p.m. CET) to discuss the preliminary data announced this morning from the ongoing Phase 1/2 trial of its mRNA-based vaccine program against SARS-CoV-2. To participate in the conference call, please dial the following numbers 10-15 minutes prior to the start of the call and provide the Conference ID: 7176269. Un

Leading innovator in nutrition and skincare, Le-Vel, is pleased to announce the promotion of Sophary Ly to Executive Vice President and Chief Financial Officer, effective immediately.

Hitachi, Ltd. (TSE: 6501, “Hitachi”) and ThinkCyte, Inc. (“ThinkCyte”) today announced that they have entered into a collaboration focused on developing an artificial intelligence (AI)-driven cell analysis and sorting system. Hitachi provides a broad range of solutions such as automated cell culture technologies to pharmaceutical companies in t